Coherus BioSciences Appoints Charlie Newton to Board of Directors
05. Mai 2022 08:31 ET
|
Coherus BioSciences, Inc.
- Biotechnology Chief Financial Officer and highly regarded former healthcare investment banker brings decades of industry experience to Coherus’ immuno-oncology strategy execution - REDWOOD CITY,...
Coherus BioSciences Announces New Employment Inducement Grants
03. Mai 2022 21:45 ET
|
Coherus BioSciences, Inc.
REDWOOD CITY, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective April 27, 2022, the compensation...
Coherus and Junshi Biosciences Receive Complete Response Letter from U.S. FDA for Toripalimab BLA
02. Mai 2022 07:00 ET
|
Coherus BioSciences, Inc.
- The CRL requests a quality process change Coherus and Junshi believe is readily addressable - - BLA resubmission anticipated by mid-summer 2022 with expected six month FDA review timeline - -...
CORRECTION - Coherus BioSciences to Report First Quarter 2022 Financial Results on May 5th, 2022
29. April 2022 16:01 ET
|
Coherus BioSciences, Inc.
REDWOOD CITY, Calif., April 29, 2022 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Coherus BioSciences, Inc. (Nasdaq: CHRS), please note in the Conference Call...
Coherus BioSciences to Report First Quarter 2022 Financial Results on May 5th, 2022
29. April 2022 08:45 ET
|
Coherus BioSciences, Inc.
REDWOOD CITY, Calif., April 29, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that its first quarter 2022 financial results will be released after...
Coherus and Junshi Biosciences Announce PD-1 Inhibitor Toripalimab Granted Orphan Drug Designation for Small Cell Lung Cancer in the United States
14. April 2022 08:30 ET
|
Coherus BioSciences, Inc.
REDWOOD CITY, Calif., and SHANGHAI, China, April 14, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) and Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”,...
Coherus and Junshi Biosciences Present Results of Phase 3 Study of Toripalimab in First Line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma at 2022 AACR Annual Meeting
08. April 2022 13:10 ET
|
Coherus BioSciences, Inc.
SHANGHAI, China, and REDWOOD CITY, Calif., April 08, 2022 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus BioSciences, Inc....
Coherus BioSciences Announces New Employment Inducement Grants
05. April 2022 16:30 ET
|
Coherus BioSciences, Inc.
REDWOOD CITY, Calif., April 05, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective March 31, 2022, the compensation...
Coherus Highlights Anticipated New Product Launches and Immuno-oncology Growth Strategy at Analyst Day Event
29. März 2022 09:15 ET
|
Coherus BioSciences, Inc.
— Multiple near-term anticipated product launches and development of innovative immuno-oncology pipeline position Coherus for long-term growth – — Introducing 2026 revenue target of $1.2...
Coherus BioSciences to Highlight New Product Pipeline, Cancer Immunotherapy Development Plans at March 29, 2022 Analyst Day Event
22. März 2022 16:30 ET
|
Coherus BioSciences, Inc.
REDWOOD CITY, Calif., March 22, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that Coherus plans to host an Analyst Day on March 29, 2022 at 9:30 a.m....